Designations: | SK-BR-3 |
|
| Depositors: | G Trempe, LJ Old |
|
| Biosafety Level: | 1 |
|
| Shipped: | frozen |
|
| Medium & Serum: | See Propagation |
|
| Growth Properties: | adherent |
|
| Organism: | Homo sapiens (human) |
|
| Morphology: | epithelial |
|
| Source: | Organ: mammary gland; breast Disease: adenocarcinoma Derived from metastatic site: pleural effusion |
|
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | HTB-30 SKBR-3 人乳腺癌細(xì)胞 |
|
| Restrictions: | The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; (212) 717-3439. |
|
| Isolation: | Isolation date: 1970 |
|
| Applications: | transfection host (Nucleofection technology from Lonza Roche FuGENE® Transfection Reagents) |
|
| Tumorigenic: | Yes |
|
| Antigen Expression: | Blood Type A; Rh+; HLA A11, Bw22(+/-), B40, B18 |
|
| DNA Profile (STR): | Amelogenin: X CSF1PO: 12 D13S317: 11,12 D16S539: 9 D5S818: 9,12 D7S820: 9,12 THO1: 8,9 TPOX: 8,11 vWA: 17 |
|
| Cytogenetic Analysis: | This is a hypertriploid human cell line with the modal chromosome number of 84, occurring in 34% of cells. Cells having 80 chromosomes also occurred at a high rate (28%); the higher ploidy cells occurred at 7.3%. This cell line has a very complex chromosome composition. Thirty-five to 40% of chromosomes in a cell complement with a modal chromosome number of 84 consisted of structurally altered marker chromosomes. Several markers are longer than chromosome N1. The origins of most of these markers, however, are not clear. Some markers may have at least three individual chromosome segments. The markers [i.e., ?der(1)t(1;21) (p13;q21) [or ?t(1q21q)], ?del(2) (q13), and t(7pter--cen--?), present in some cells only] were the only ones in which portions of chromosome segments could be identified. Most cells had about three normal X chromosomes and five or more N7. The structurally normal N1, N14 and N17 were generally absent. |
|
| Isoenzymes: | AK-1, 1-2 ES-D, 1 G6PD, B GLO-I, 2 PGM1, 1-2 PGM3, 1 |
|
| Age: | 43 years |
|
| Gender: | female |
|
| Ethnicity: | Caucasian |
|
| Comments: | No virus particles. Ultrastructural features include microvilli and desmosomes, glycogen granules, large lysosomes, bundles of cytoplasmic fibrils. The SK-BR-3 cell line overexpresses the HER2/c-erb-2 gene product. [30816] |
|
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
|
| Subculturing: | Protocol:Remove and discard culture medium. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
HTB-30 Subc*tion Ratio: A subc*tion ratio of 1:2 is recommendedMedium Renewal: 2 to 3 times per week |
|
| Preservation: | Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor temperature |
|
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2007 recommended serum:ATCC 30-2020 purified DNA:ATCC 45520 purified DNA:ATCC 45521 derived from same individual:ATCC CRL-2351 purified DNA:ATCC HTB-30D |
|
| References: | 21869: . Human tumor cells in vitro. New York: Plenum Press; 1975. 22468: Trempe GL. Human breast cancer in culture. Recent Results Cancer Res. 57: 33-41, 1976. PubMed: 1013510 22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871 22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080 23226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212 30816: Hudziak RM, et al. Monoclonal antibodies directed to the Her2 receptor. US Patent 5,677,171 dated Oct 14 1997 32275: Littlewood-Evans AJ, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57: 5386-5390, 1997. PubMed: 9393764 32567: Chavany C, et al. p185erbB2 binds to GRP94 in vivo. J. Biol. Chem. 271: 4974-4977, 1996. PubMed: 8617772 |
|
|